↓ Read PDF
01 · ABSTRACT

Abstract

Objective To evaluate the performance of the systematic (SBx) and targeted prostate biopsy (TBx) in detecting prostate cancer (PCa) and significant prostate cancer (csPCa) and including upfront risk stratification with PSA Density (PSAD) in a biopsy naïve cohort of Chinese men.

Methods A total of 348 men from two medical centers were available for analyses.  All men underwent a mpMRI scan based on an elevated PSA and/or abnormal digital rectal examination (DRE). A total of 150 men received both SBx and TBx prostate biopsy (PIRADS >= 3). In these men the detection ratio was calculated as the PCa and csPCa prevalence of the TBx strategy divided by the prevalence of PCa and csPCa of the SBx + TBx strategy. For PSAD analyses the percentage missed csPCa were plotted against the clinically relevant thresholds of PSAD (range 0.01 – 0.20).

Results In the men with PIRADS >= 3, a total of 89 PCa cases (59 being csPCa) were detected. The TBx alone strategy detected 74 of all PCa, leading to a detection ratio of 0.83 (95% CI 0.74-0.90). For csPCa these numbers were 48 of the total 59 csPCa cases, i.e a detection ratio of  0.81 (95% CI 0.69-0.90).With the focus on avoiding missing csPCa diagnoses a  cut-off of PSA D 0.10 seemed optimal in this cohort, leading to a reduction of 15% of all referrals, missing 6% of all PCa and 2% of csPCa. A similar cut-off of PSAD holds if also men with PIRADS >= 2 were included.

Conclusion In this Chinese cohort of biopsy naïve men a TBx approach can aid in improved detection of csPCa. Omitting SBx would results in missing csPCa cases. An upfront risk stratification step with the use of PSAD is advised although the optimal PSAD cut-off in Asian men most likely differs from the generally advised cut-off of 0.15 ng/ml/ml.

↓ Read PDF
02 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 9 No 8 (2021): Vol.9 Issue 8 August 2021
SectionResearch Articles
Published11 August 2021
DOI10.18103/mra.v9i8.2519
ISSN2375-1924
03 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 3.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

KZ

Kai Zhang

Department of Urology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; Department of Urology, Beijing United Family Hospital and Clinics, Beijing, China

ZS

Zijian Song

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China : Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China

SR

S. Remmers

Department of Urology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands

RC

Rui Chen

Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China

GZ

Gang Zhu

Department of Urology, Beijing United Family Hospital and Clinics, Beijing, China

MR

Monique J Roobol

Department of Urology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands

Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗